Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Mathias Dewatripont Clear advanced filters
  • In just a few weeks’ time, leaders across the globe will have to start making decisions about lifting lockdown policies, with considerable social, economic and political consequences. We propose a framework for what is arguably the most difficult health challenge that governments have faced since the beginning of this century: a responsible lockdown exit strategy.

    • Marius Gilbert
    • Mathias Dewatripont
    • Michel Goldman
    Comments & Opinion
    Nature Medicine
    Volume: 26, P: 643-644
  • Despite major advances in cancer research, we are falling short in bringing innovative medicines to children with cancer. We propose a new business model to incentivize investors, private companies and public organizations to invest in drug development for paediatric cancers.

    • Sam Daems
    • Hilde Stevens
    • Michel Goldman
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 22, P: 769-770
  • With the growing number of efficient gene therapies on the market, now is the time to take actions to ensure reasonable pricing of gene therapy products. Among these, we propose to incentivize gene therapy companies to adopt a status that translates their corporate social responsibility into concrete commitments.

    • Alain Fischer
    • Mathias Dewatripont
    • Michel Goldman
    Comments & Opinion
    Nature Medicine
    Volume: 25, P: 1813-1814